Answers are grounded in this paper and cite their sources.
Despite the neutral primary outcome in the PROMINENT trial, pemafibrate may offer benefits for microvascular ischemic complications, NAFLD, and diabetic microangiopathy.
The neutral result of the PROMINENT trial has led to questions about the future for pemafibrate. This commentary discusses possible reasons for the lack of benefit observed in the trial. There were, however, indicators suggesting therapeutic potential in microvascular ischaemic complications associated with peripheral artery disease, with subsequent analysis showing reduction in the incidence of lower extremity ischaemic ulceration or gangrene. Reassurance about the safety of pemafibrate, together with emerging data from PROMINENT and experimental studies, also suggest benefit with pemafibrate in non-alcoholic fatty liver disease (alternatively referred to as metabolic dysfunction-associated steatotic liver disease) and microangiopathy associated with diabetes, which merit further study.
No takes yet. Share an insight, caveat, or question.
Fruchart et al. (2024) conducted a review in Type 2 diabetes mellitus with mixed dyslipidaemia (n=10,497). Pemafibrate vs. Placebo was evaluated on Composite of nonfatal myocardial infarction, ischaemic stroke, coronary revascularization, or death from cardiovascular causes (HR 1.03, 95% CI 0.91 to 1.15).
Synapse has enriched 10 related papers. Consider them for comparative context: